Massimo Trucco, MD, on the Potential of Islet Cell Transplant

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.

Children Treated With Zolgensma for Presymptomatic SMA Achieve Age-Appropriate Motor Milestones

All children in the phase 3 SPR1NT study achieved the primary end point of independent sitting.

Developing Invariant Natural Killer T Cells for Multiple Myeloma, GVHD

Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed different indications for the iNKT therapy AgenT-797.

Case Study: Neoantigen TCR Gene Therapy Yields Metastatic Pancreatic Cancer Regression

The treated patient achieved an overall partial response of 72% in tumor regression.

Keith Fargo, PhD, on Potential Treatment Avenues for Charcot-Marie-Tooth

The chief scientific officer of the CMT Research Foundation discussed investigative cell and gene therapy approaches for treating CMT.

IND Cleared for γδ T-Cell Therapy in Non-Hodgkin Lymphoma

ACE1831 will soon be evaluated in a phase 1, first-in-human, clinical trial.